THESE Préparée sous la direction du Professeur Associé Urs Scherrer
Méthodes : Chez 27 enfants et 29 adultes non acclimatés, nous avons évalué la présence et la sévérité de l'AMS durant les 48 premières heures après une montée rapide à 3450m, et ceci en deux occasions distantes de 9 à 12 mois.
Reproducibility of Acute Mountain Sickness in Children and Adults: A Prospective Study
WHAT'S KNOWN ON THIS SUBJECT: Although a history of previous acute mountain sickness is often used for providing advice and recommending its prophylaxis during subsequent exposure, the intraindividual reproducibility of acute mountain sickness during repeated high-altitude exposure has never been examined in a controlled study.
WHAT THIS STUDY ADDS:
A history of acute mountain sickness strongly predicts future illness in adults but not in children.
Advice to avoid re-exposure to high altitude or prescription of prophylactic medications is not indicated in children.
abstract OBJECTIVE: Although a history of previous acute mountain sickness (AMS) is commonly used for providing advice and recommending its prophylaxis during subsequent exposure, the intraindividual reproducibility of AMS during repeated high-altitude exposure has never been examined in a prospective controlled study.
METHODS:
In 27 nonacclimatized children and 29 adults, AMS was assessed during the first 48 hours after rapid ascent to 3450 m on 2 consecutive occasions 9 to 12 months apart.
RESULTS:
During the first exposure, 18 adults (62%) and 6 children (22%) suffered from AMS; during the second exposure, 14 adults (48%) and 4 children (15%) suffered from this problem (adults versus children, P Յ .01). Most importantly, the intraindividual reproducibility of AMS was very different (P Ͻ .001) between children and adults. None of the 6 children having suffered from AMS during the first exposure suffered from AMS during the second exposure, but 4 children with no AMS during the first exposure did experience this problem during the second exposure. In contrast, 14 of the 18 adults who suffered from AMS on the first occasion also presented with this problem during the second exposure, and no new case developed in those who had not experienced AMS on the first occasion.
CONCLUSIONS:
In adults, a history of AMS is highly predictable of the disease on subsequent exposure, whereas in children it has no predictive value. A history of AMS should not prompt practitioners to advise against reexposure to high altitude or to prescribe drugs for its prophylaxis in children. Accepted for publication Feb 8, 2011 Travel to high-altitude destinations for business and recreational purposes has become increasingly popular, and large numbers of persons are exposed to high-altitude-related medical risks. Among these risks, acute mountain sickness (AMS) is by far the most frequent problem occuring in more than 80% of tourists arriving by plane at 3740 m. 1 AMS is a syndrome of nonspecific symptoms, including headache and 1 or more of the following: fatigue, anorexia and nausea, dizziness, and sleep disturbance, often developing within hours after arriving at altitudes Ͼ2500 m. 2 It affects otherwise healthy persons and in most cases resolves spontaneously, but in some cases it progresses to life-threatening highaltitude cerebral edema. 2 A history of AMS is often used for providing advice about the risk of its reoccurrence and deciding about the indication for its pharmacologic prophylaxis during subsequent high-altitude exposure; to the best of our knowledge, however, there is surprisingly little information on the intraindividual reproducibility of AMS during repeated high-altitude exposure in adults, 3, 4 and no such information in children. In a prospective, controlled study, we therefore assessed the prevalence of AMS in nonacclimatized children and adults with no previous high-altitude experience during the first 48 hours after rapid ascent by train to 3450 m on 2 consecutive occasions 9 to 12 months apart.
METHODS

Study Group
We studied 27 healthy Swiss children (mean All participants had regular physical activity and were living at altitudes Ͻ700 m. None of the participants was obese (BMI Ͼ30), had slept at high altitude (Ͼ1500 m) during the 3 months preceding the 2 studies, none had ever spent a night at an altitude Ͼ2000 m, and none was taking any medication during the studies. The experimental protocol was approved by the Institutional Review Board on Human Investigation, and all participants (including the children as well as their parents) provided written informed consent.
The study took place on 2 consecutive occasions 9 to 12 months apart. The participants ascended with a 2 1 ⁄ 2-hour train ride that took them from 568 m to the Jungfraujoch International High Altitude Research Station at 3450 m, where they arrived in the early afternoon. They then spent 2 days and 2 nights in small bedrooms at the research station. During the stay, all participants received the same diet, and care was taken to assure adequate fluid intake (Ն2 L/d). Adult participants refrained from alcohol consumption at high altitude. Physical activity was standardized. On the day of arrival, the participants rested quietly and visited the research station and the adjacent installations. In the afternoon of the second day, all participants made an easy 2-to 2 1 ⁄ 2-hour walk to the Mönchsjoch Hut located at 3650 m. On the morning before descent the participants remained within the research station.
Evaluation for Acute Mountain Sickness
The presence of AMS was assessed on the evening of the day of arrival and on the 2 following mornings (at 6, 18, and 42 hours after arrival at high altitude) with a French version of the Lake Louise Scoring System, a selfassessment questionnaire, 5 under the supervision of a trained examiner.
Briefly, for each of the 5 items (headache, gastrointestinal symptoms, fatigue, dizziness, and sleep disturbance), the participants noted a score between 0 and 3, with 0 indicating the absence of the symptom; 1, mild symptoms; 2, moderate symptoms; and 3, severe, incapacitating symptoms. For children younger than 12 years of age, a verbally adapted version of the score was used (Lake Louise age-adjusted symptom score). 6 Participants were considered suffering from AMS if they were experiencing headache and scored Ն3 on the selfassessment questionnaire (the maximal score for the questionnaire was 15) on at least 1 of the 3 assessments. 5
Measurement of Arterial Oxygen Saturation
Transcutaneous arterial saturation and heart rate were measured at a fingertip with a pulse oximeter (OxiMax N-595, Nellcor, Pleasanton, CA).
Statistical Analysis
Statistical analysis was performed by using paired and unpaired Student's t tests for within-and between-group comparisons of normally distributed variables. The Fisher's exact test was used for between-group comparisons of the prevalence and reproducibility of AMS. Predictive values and confidence intervals (CIs) were calculated as previously described. 7 Data are expressed as mean (SD). A P value Ͻ 0.05 was considered to indicate statistical significance.
RESULTS
Arterial oxygen saturation at high altitude was similar in children (90% The overall prevalence of AMS was significantly higher in adults than in children. During the first exposure, 18 of the 29 adults (62%) and 6 of the 27 children (22%) suffered from AMS (P ϭ .003); during the second exposure, 14 adults (48%) and 4 children (15%) suffered from this problem (P ϭ .01) (Fig 1) . The intraindividual reproducibility of AMS was markedly different between children and adults (P Ͻ .001; Fig 1) . In children, a history of AMS did not predict its recurrence, because none of the 6 children having suffered from AMS during the first exposure suffered from AMS during the second exposure. However, 4 children, who had not suffered from AMS during the first exposure, experienced it during the second exposure (positive predictive value: 0% [95% CI: 0%-48%]; negative predictive value: 81% [95% CI: 57%-94%]). In contrast, AMS was very reproducible in adults; 14 of the 18 adults who suffered from AMS on the first occasion also presented with this problem during the second exposure, and no new cases developed in those adults who had not suffered from AMS on the first occasion (positive predictive value: 78% [95% CI: 52-93%]; negative predictive value: 100% [95% CI: 68%-100%]). In children and adults, the prevalence of AMS was similar in both genders.
Among the participants who suffered from AMS, the severity of the disease was similar in children and adults during both exposures; during the first exposure, the mean (SD) score was 3.8 (1.2) (95% CI: 3-6) in children and 4.6 (1.4) (95% CI: 3-8) in adults (P ϭ .24); during the second exposure it was 4.3 (1.0) (95% CI: 3.0 -5.0) and 4.4 (1.4) (95% CI: 3.0 -7.0), respectively (P ϭ .78). None of the subjects developed clinical signs of high-altitude cerebral or pulmonary edema.
Independent of whether AMS was present or not, headache and sleep disturbances were more severe (P Ͻ .001) in adults than in children: mean headache score was 0.86 (0.83) versus 0.30 (0.57) (95% CI: 0.0 -2.1 vs 0.0 -2.0) and sleep disturbance score was 1.07 (0.83) versus 0.39 (0.68) (95% CI: 0.0 -2.1 vs 0.0 -2.0), whereas the scores for gastrointestinal symptoms, fatigue, and dizziness were similar in the 2 groups. Moreover, headache was also significantly (P ϭ .006) more frequent in adults (23 of 29) than in children (11 of 27), whereas the frequency of the other 4 symptoms making up for AMS was similar in children and adults.
DISCUSSION
AMS is a frequent problem in travelers ascending to high-altitude locations. Its occurrence during previous exposure is commonly used for providing advice and deciding about the indication for its prophylaxis during subsequent exposures, but there is little information on its intraindividual reproducibility. 2 In this prospective controlled study, we found that the intraindividual reproducibility of AMS was very different between children and adults. Although nearly 80% of the adults who had suffered from AMS during the first exposure also suffered from this problem during the second exposure, none of the children who had suffered from AMS on the first occasion suffered from this problem again. These findings indicate that AMS history is useful for providing advice and to guide the prescription of drugs for its prophylaxis in adults but not in children.
Our data indicate that, in adults, AMS history not only allows to predict with a high probability its recurrence during subsequent exposure; it also allows excluding its occurrence in those who had not suffered from this problem, because none of the adults who had not suffered from AMS during the first exposure suffered from this problem during the second exposure. In contrast, in children not suffering from AMS during the first exposure did not exclude its occurrence during subsequent exposure, as demonstrated by the 4 children who were asymptomatic during the first exposure but suffered from AMS during the second exposure. The reason for this difference of the intraindividual reproducibility of AMS between children and adults is not clear but could possibly involve variability in the self-perception of illness in children. 8 The present data also provide the first direct comparison of the prevalence of AMS between children and adults under strictly controlled conditions. The markedly lower prevalence of AMS in children than in adults was unexpected, because it has been suggested that the incidence of AMS may be inversely related to age. 9 This finding at MME Martine Leplay Fontana on September 7, 2011 pediatrics.aappublications.org Downloaded from does not seem to be related to a particularly high prevalence of AMS in adults in the present study, because it was similar or lower than the one reported in previous studies. 1, 10 It was also not related to an unexpectedly low prevalence of AMS in children in the present study, because the prevalence of AMS was similar to the one reported in an earlier study at this altitude. 11 In this controlled study, we were able to control for several important confounding factors that may facilitate or mimic AMS. Exercise represents a risk factor for AMS, and more intense exercise has been suggested to explain the higher prevalence of AMS in young versus elderly mountaineers in an earlier study. 12 Here, we found that when exercise is controlled, the AMS prevalence was lower in children than in adults. In adults, alcohol consumption may aggravate or mimic AMS. 13, 14 This factor did not come into play in the present study, because adults refrained from alcohol at high altitudes. A chamber study suggested that obesity may represent a risk factor for AMS in adults. 15 None of the subjects in our study was obese.
CONCLUSIONS
Current guidelines suggest pharmacologic prophylaxis for AMS in persons rapidly ascending to high altitude, 2 in particular in the presence of a history of previous AMS. The findings of the present controlled prospective study provide the scientific foundation for this attitude in adults. In contrast, in children, AMS history is not a useful guide for prescribing or withholding pharmacologic prophylaxis. Moreover, the low prevalence, mild manifestation, and benign course of AMS in children rapidly ascending to this altitude at which major tourist destinations are located worldwide suggest that pharmacologic prophylaxis for AMS is not needed, and the use of drugs can be reserved for the treatment of symptoms, if they appear. Finally and most importantly, in children, a history of a previous AMS should also not prompt practitioners to advise against reexposure to high altitudes.
